Contrasting ProPhase Labs (NASDAQ:PRPH) & SciSparc (NASDAQ:SPRC)

ProPhase Labs (NASDAQ:PRPH) and SciSparc (NASDAQ:SPRC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Risk and Volatility

ProPhase Labs has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Comparatively, SciSparc has a beta of 2.71, suggesting that its share price is 171% more volatile than the S&P 500.

Earnings and Valuation

This table compares ProPhase Labs and SciSparc”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06 million	0.13	-$53.36 million	($3.90)	-0.03
SciSparc	$860,000.00	3.19	-$12.18 million	N/A	N/A

SciSparc has lower revenue, but higher earnings than ProPhase Labs.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ProPhase Labs and SciSparc, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1	0	0	0	1.00
SciSparc	1	0	0	0	1.00

Profitability

This table compares ProPhase Labs and SciSparc’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
SciSparc	N/A	N/A	N/A

Insider and Institutional Ownership

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 25.1% of SciSparc shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 1.5% of SciSparc shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

SciSparc beats ProPhase Labs on 7 of the 9 factors compared between the two stocks.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.